In conclusion, the fusion peptide Tat‐SIRT5‐CTM may be a promising therapeutic approach for the clinical treatment of ischemic stroke and possibly other types of neuroinflammatory disorders. The gene discussed is SIRT5; the disease is ischemic stroke.